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Edited by Michael R. BubbAbstract Bcl-2 contains an unusually long loop between the
ﬁrst and the second helices. This loop has been shown to be
highly ﬂexible based on NMR and X-ray crystallographic anal-
yses of this region. Bcl-2 is regulated at the posttranslational le-
vel through phosphorylation of speciﬁc residues within the
ﬂexible loop. The biological role and posttranslational modiﬁca-
tions of the loop of Bcl-2 is currently unclear. FK-506 binding
protein 38 (FKBP38) has been reported to interact with Bcl-2,
suggesting that FKBP38 could act as a docking molecule to
localize Bcl-2 at the mitochondrial membrane [Shirane, M. and
Nakayama, K.I. (2003) Inherent calcineurin inhibitor FKBP38
targets Bcl-2 to mitochondria and inhibits apoptosis. Nat. Cell
Biol. 5, 28–37]. Here, we investigated the molecular interaction
between FKBP38 and Bcl-2, and demonstrated that Bcl-2 inter-
acts with FKBP38 through the unstructured loop, and the inter-
action appears to regulate phosphorylation in the loop of Bcl-2.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis is an essential and well-orchestrated cellular regu-
latory mechanism in which pro- and antiapoptotic proteins are
involved at various stages. The proteins of Bcl-2 family are
central to the regulation of apoptosis [1–4]. Three-dimensional
structures of Bcl-Xl and Bcl-2 reveal that such proteins contain
an elongated hydrophobic cleft through which the antiapopto-
tic proteins and their ligands interact to form heterodimers
[5,6]. Another intriguing feature from the three-dimensional
structures is that Bcl-2 and Bcl-Xl contain a disordered long
loop with about 60 amino acid residues between the ﬁrst and
the second helices. This ﬂexible loop has been shown to be
unstructured based on NMR or X-ray crystallographic analy-
ses on this region [5].
Recently, this ﬂexible loop has been shown to be regulated at
the posttranslational levels, such as phosphorylation and ubiq-
uitin-dependent degradation, in response to diverse external
stimuli [7–10]. Proteins containing regions of denatured or ran-*Corresponding author. Fax: +65 6791 3856.
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to cleavage by cellular protease [11,12]. Therefore, it has been
suspected that the long disordered loop of Bcl-2 and Bcl-Xl is
shielded or otherwise protected from rapid degradation by
other cellular proteases [7]. Currently, the association of puta-
tive chaperones or regulatory molecule including kinases with
the unstructured loop is not well understood. Recently, it has
been shown that immunosuppressant FK-506 binding protein
38 (FKBP38) is co-localized with Bcl-2 and Bcl-Xl at the mito-
chondria, suggesting that FKBP38 is a potential docking mol-
ecule for the antiapoptotic proteins [14]. However, details and
characteristics of the molecular interaction between FKBP38
and the antiapoptotic proteins remain to be explored. In this
study, we have performed the characterization of recombinant
human FKBP38 and investigated the nature of molecular
interaction between FKBP38 and Bcl-2 to understand a possi-
ble, alternative mechanism of apoptotic regulation Bcl-2.2. Materials and methods
2.1. Materials
Antibodies against Bcl-2 and Bcl-Xl were purchased from Santa
Cruz Biotech (Santa Cruz, CA, USA). Antibody against human
FKBP38 was a kind gift from Keiichi I. Nakayama. Ni2+–NTA resin
and RNeasy Mini Kit were from Qiagen (Hilden, Germany). Immune-
Star Chemiluminescent protein detection system and protein molecular
weight marker were from Bio-Rad Laboratories (Hercules, CA, USA).
c-Jun-N-terminal kinase 1a1 (JNK) was from Upstate (Lake Placid,
NY, USA). [c-33P]ATP (3000 Ci/mmol), HiPrep 16/60 Sephacryl S-
200, Superdex 75 gel ﬁltration column, and GST Purifcation Module
were from Amersham Biosciences (Buckinghamshire, UK). Phenyl-
methylsulfonyl ﬂuoride, reverse transcription-polymerase chain reac-
tion (RT-PCR) kit and restriction enzymes were from Roche
(Indianapolis, IN, USA). Ethylene glycol-bis-(b-aminoethyl ether)-
N,N,N 0,N 0-tetraacetic acid (EGTA) and other chemicals were pur-
chased from Sigma–Aldrich (St. Louis, MO, USA). Escherichia coli
BL21 (DE3) and carbenicillin were from Invitrogen (Carlsbad, CA,
USA). pET29b was from Novagen (Madison, WI, USA). Synthetic
Dropout (SD) medium was from Clontech (Palo Alto, CA, USA). Iso-
porpyl-thio-b-D-galactopyranoside (IPTG) was from Promega (Madi-
son, WI, USA).2.2. cDNA constructs
The cDNAs coding for human FKBP38 and Bcl-2 lacking the trans-
membrane domains (FKBP38DTM and Bcl-2DTM) were ampliﬁed
using mRNA from MCF-7 breast cancer cell by RT-PCR. The cDNA
coding for human Bcl-Xl has been previously described [5]. The ampli-
ﬁed PCR products were digested with restriction enzymes NdeI and
XhoI and engineered into pACYC184 and pET29b, respectively. The
cDNA of FKBP38DTM was also cloned into pGEX-4T-1-m1to generate
GST fusion protein. The following primers were used for amplifyingblished by Elsevier B.V. All rights reserved.
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CACGCTGGGAGAACGGGGTAC-3 0 (forward primer for Bcl-2);
5 0-GCGAAGCTCTCGAGCTATCACCGCATGCTGGGGCCGTA-
CAGTTC-30 (reverse primer for Bcl-2); 5 0-CACTCAGCATATGGG-
ACAACCTCCGGCGGAGGAGGCT-3 0 (forward primer for
FKBP38); 5 0-GCGAAGCTCGAGGTTGCCCAGCATTTTCCGGT-
ACAA-30 (reverse primer for FKBP38). For the construction of dele-
tion mutants of Bcl-2 in the ﬂexible loop region, PCR was performed
according to the published protocol [6] using pET29/Bcl-2 as a tem-
plate and 5 0 phosphorylated forward and reverse primers as shown
in Table 1. The ampliﬁed DNA fragments were transferred into
pET16b to generate His-tag at the N-terminus of proteins. Mutations
were conﬁrmed by dideoxy DNA sequencing.2.3. Co-expression and puriﬁcation of FKBP38 and Bcl-2 complexes
The recombinants Bcl-2 and FKBP38 were co-transformed into
E. coli BL21 (DE3) cells. The proteins were induced by adding IPTG
to 1 mM when Abs600 was 0.8–1.0. After 2-h induction at 30 C, the
cells were harvested by centrifugation at 8000 · g for 10 min. The cells
were suspended in the suspension buﬀer (20 mM phosphate buﬀer, pH
7.8, 0.5 M NaCl, and 5 mM 2-mercaptoethanol) and sonicated for
20 min. The cell lysate was centrifuged at 20000 · g for 25 min. The
supernatant was loaded to Ni2+–NTA column and the column was
washed with 30 column volumes of the washing buﬀer (20 mM phos-
phate, pH 7.2, 1 M NaCl, 20 mM imidazole, and 5 mM 2-mercap-
toethanol) and eluted with the elution buﬀer (20 mM phosphate, pH
6.0, 0.5 M NaCl, 5 mM 2-mercaptoethanol, and 0.5 M imidazole).
The proteins were analyzed by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE). The amount of proteins were deter-
mined by Bradford dye assay kit from Bio-Rad Laboratories.2.4. Western blot analysis
Proteins were separated on 12.5% SDS–PAGE and transferred to
polyvinylidene diﬂuoride (PVDF) membrane. The PVDF membrane
was ﬁrst blocked with 1% milk in TBS buﬀer (20 mM Tris–HCl, pH
8.0, 150 mM NaCl) and then incubated with primary antibody in
TBS buﬀer containing 0.2% milk for 2 h at 37 C. The immunoreactiv-
ity was detected using Immune-Star Chemiluminescent protein detec-
tion system (Bio-Rad Laboratories).2.5. Phosphorylation of Bcl-2 and Bcl-Xl
0.5 lg of the puriﬁed Bcl-2, its mutants, corresponding FKBP38/Bcl-
2 complex Bcl-Xl, and corresponding FKBP38/Bcl-Xl complexes were
incubated with 50 ng of JNK for 4 h at 30 C in a buﬀer containing
10 mM Tris–HCl, pH 7.5, 25 mM MgCl2, 1 mM EGTA, 1 mM
ATP, and 1 lCi [c-33P]ATP (3000 Ci/mmol). The phosphorylated sam-
ples were analyzed on 12.5% SDS–PAGE at room temperature, dried,
and followed by autoradiography for visualization.Table 1















All forward and reverse primers were phosphorylated at the 5 0-terminus.2.6. Calcineurin assay
The plasmids pBB131/MEKK-C and NpT7-5/a-SAPK+MEK4 for
expression of active JNK in E. coli were kindly provided by Prof. Mel-
anie H. Cobb (University of Texas Southwestern Medical Center,
USA). The puriﬁcation of a large amount of active JNK was per-
formed according to their protocol [17]. Phosphorylation of Bcl-2
using same protocol as described above except using 2 mM cold
ATP. The phosphorylated Bcl-2 (P-Bcl-2) was further puriﬁed by
Superdex 75 gel ﬁltration column chromatography. The plasmid
pETCNa encoding cancineurin was kindly provided by Prof. Jun O.
Liu (Johns Hopkins University, USA). The yeast myristoyl-CoA: pro-
tein N-myristoyltransferase (NMT) was PCR ampliﬁed using yeast
genomic as template and resulting PCR product was inserted into
pACDUET (Novagen) with NcoI and HindIII to generate pACD-
UET/NMT. The pETCNa was co-transformed with pACDUET/
NMT. The puriﬁcation of the calcineurin and the dephosphorylation
reaction were carried out as described previously [18].
2.7. Yeast two-hybrid assay
FKBP38 was cloned into pAS2-1 using BamHI and XhoI restriction
enzymes to generate GAL4 activation domain fusion protein. Bcl-2
and Bcl-2 loop deletion mutants were cloned into pACT2 using NdeI
and SalI restriction enzymes to generate GAL4 DNA binding domain
fusion proteins. Saccharomyces cerevisiae strain PJ69-4A (MATa his 3
leu 2 ura 3 trp 1 gal4D gal 8D met 2:: GAL7-lacZ GAL2-Ade 2
LYS2::GAL1-his 3) was grown in YPD medium containing 1% yeast
extract, 2% polypeptone, and 2% glucose. Cells were grown on the
minimal synthetic dropout (SD) medium lacking Leu, Trp or SD med-
ium lacking Leu, Trp, His to check protein–protein interaction.
2.8. GST pull down assay
GST-FKBP38DTM was puriﬁed by the glutathione–Sepharose 4B
resin, and further puriﬁed by Superdex 75 gel ﬁltration column chro-
matography. 10 lg of GST-FKBP38DTM was incubated with 3 lg
of Bcl-2 or P-Bcl-2 on ice for 4 h, respectively. Then protein samples
were mixed with 40 ll of glutathione–Sepharose 4B resin on ice for
2 h, and washed with PBS (140 mM NaCl, 2.7 mM KCl, 10.1 mM
Na2HPO4, and 1.8 mM KH2PO4). The protein bound resin was eluted
with elution buﬀer (10 mM reduced glutathione, 50 mM Tris–HCl, pH
8.0). The eluted samples were analyzed in 12.5% SDS–PAGE and fol-
lowed by Western blotting analysis.3. Results
3.1. Expression and puriﬁcation of recombinant human FKBP38
The cDNA coding for human FKBP38 was obtained from
breast cancer MCF-7 cells, and showed that the sequence is
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family proteins demonstrate the lack of conservation of resi-
dues involved in FK-506 binding and peptidyl prolyl cis–trans
isomerase (PPIase) activity [13] (Fig. 1). Human FKBP38 lack-
ing the transmembrane domain (FKBP38DTM) was expressed
in E. coli cells, and puriﬁed by Ni2+–NTA aﬃnity resin and
subsequently further puriﬁed by Sephacryl S-200 gel ﬁltration
column chromatography. As shown in Fig. 2A, we were able
to purify the FKBP38 to near homogeneity. The puriﬁed pro-
tein was stable over a period of one month at 4 C.
3.2. Complex formation between FKBP38 and Bcl-2
To probe speciﬁc molecular interaction between FKBP38
and Bcl-2, the plasmids for FKBP38 with His-tag, and Bcl-2
without His-tag were constructed for the conﬁrmation of com-
plex formation as described in Section 2. The recombinants
Bcl-2 and FKBP38 were co-expressed in E. coli BL21 (DE3)
cells, puriﬁed by Ni2+–NTA aﬃnity resin (Fig. 2B), and con-
ﬁrmed by Western blot using anti-Bcl-2 and anti-FKBP38
antibodies (Fig. 2C). FKBP38 contains His-tag at the C-termi-
nus, while Bcl-2 has no tag. The only way to purify Bcl-2 on
the Ni2+–NTA aﬃnity is through the formation of the complex
between Bcl-2 and FKBP38. The Western blot results con-
ﬁrmed that the two eluted bands from the aﬃnity column were
FKBP38 and Bcl-2, respectively. Taken together, these data
suggest that recombinant human FKBP38 bound to Bcl-2,
when they were co-expressed in bacterial cells.
3.3. Identiﬁcation of speciﬁc interaction of FKBP38 with Bcl-2
To further deﬁne and identify a region on Bcl-2 responsible
for the molecular interaction with FKBP38, several mutant
forms of Bcl-2 were constructed, based on known three-dimen-
sional structural information (Fig. 3A). In this study, we have
focused on the ﬂexible loop of Bcl-2. The wild type Bcl-2 and
mutant forms of Bcl-2 with various deletions in the unstruc-
tured loop were expressed and tested their abilities to interact
with FKBP38. The results showed that all mutants constructedFig. 1. Multiple sequence alignment of FKBP family proteins: FKBP51(JC
FKBP38(AAB00102). The multiple protein alignment was generated by Vec
FKBP/FK506 [15] and sequence alignment among FKBP family proteins,
reverse triangles (.), and those which are involved in interaction with FK-50
protein data base accession number is indicated in parenthesis correspondinin this study could be puriﬁed in soluble forms as shown in
Fig. 3B and were stable during the experiment. From the
column binding study, the wild type Bcl-2 showed clear bind-
ing to FKBP38, whereas the loop deletion mutants, Bcl-
2D(V35-V89):6A, in which the residues from V35 to V89 were
removed and six alanine residues were replaced instead, and
Bcl-2D(H55-V89), in which the residues from H55 to V89 were
removed, failed to bind to FKBP38 (Fig. 3C). Bcl-2D(V35-
V89):6A and Bcl-2D(H55-V89) lack three known phosphoryla-
tion sites, T56, S70, S87, in the ﬂexible loop of Bcl-2 [10]. The
deletion mutants Bcl-2D(P65-V89), Bcl-2D(V35-D64), and Bcl-
2D(V35-G79) showed binding to FKBP38 to a considerably re-
duced degree. To further conﬁrm the interaction of FKBP38
with Bcl-2, yeast two-hybrid experiments were performed
(Fig. 3D and E). The wild type Bcl-2-containing yeast cells
showed growth in the selection media whereas Bcl-2Dloop:6A
and Bcl-2D(H55-V89) failed to grow in the selection media.
The results regarding Bcl-2D(V35-V89):6A and Bcl-2D(H55-
V89) mutants were consistent with the column binding assays
shown in Fig. 3C. Other loop deletion mutants, Bcl-2D(P65-
V89), Bcl-2D(V35-D64), Bcl-2D(V35-G79), unlike the column
binding experiments, showed growth under the selection media
used in the yeast two-hybrid study, like the same manner as
seen in the wild type Bcl-2. The discrepancy between two ap-
proaches regarding Bcl-2D(P65-V89), Bcl-2D(V35-D64), Bcl-
2D(V35-G79) could be attributed to the sensitivity diﬀerence
between two procedures. Taken together, our results suggest
that the molecular interaction of FKBP38 with Bcl-2 would re-
quire at least one phosphorylation site or surrounding se-
quences of the known three phosphorylation sites (T56, S70,
S87) in the unstructured loop of Bcl-2.
3.4. FKBP38 aﬀects phosphorylation of the unstructured loop of
Bcl-2
The phosphorylation of Bcl-2 was found to be associated
with its ﬂexible loop and JNK has been reported to be
one of kinases responsible for the phosphorylation of T56,5422), FKBP52(A46437), FKBP12(A35780), FKBP25(JQ1522), and
tor NTI Align X (Informax). Based on three-dimensional structure of
the residues in the active pocket for binding FK506 are indicated by
6 through hydrogen bonding are indicated by ﬁlled circles (d). NCBI
g to the FKBP family proteins.
Fig. 2. Molecular interaction between FKBP38 and Bcl-2. (A) Human
FKBP38 lacking the transmembrane domain was expressed in E. coli
BL21 (DE3) cells, puriﬁed by Ni2+–NTA aﬃnity resin, and subse-
quently further puriﬁed by Sephacryl S-200 (Pharmacia) gel ﬁltration
column chromatography. (A) Protein samples at various stages were
analyzed by 12.5% SDS–PAGE: 1, MWmarkers; lanes 2, 3, before and
after IPTG induction; lanes 4, 5, loading sample before Ni2+–NTA and
eluted fraction after Ni2+–NTA aﬃnity puriﬁcation, respectively; lane
6, FKBP38 after S-200. (B) The FKBP38 with His-tag and Bcl-2 with
no-tag were co-expressed in E. coli BL21(DE3) cells, puriﬁed by Ni2+–
NTA aﬃnity resin, and analyzed in 12.5% SDS–PAGE: 1, MW
markers; lanes 2, 3, before and after IPTG induction; lanes 4, 5,
loading sample before Ni2+–NTA and eluted fraction after Ni2+–NTA
aﬃnity. (C) Complex formation of FKBP38 with Bcl-2. The loading
sample and eluted fraction from Ni2+–NTA were analyzed by Western
blot with antisera to FKBP38 and Bcl-2.
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this study, to investigate the role of FKBP38 in connection
with the posttranslational regulation of the Bcl-2 loop, Bcl-2 phosphorylation experiment was performed using JNK
and the puriﬁed Bcl-2, its truncation mutants in the ﬂexible
loop, and the corresponding FKBP38–Bcl-2 complex as sub-
strates. The puriﬁed Bcl-2 mutants were soluble and stable
(Fig. 4A). The phosphorylation results showed that JNK
was able to phosphorylate the puriﬁed Bcl-2 in more than
one positions, evidenced by multiple Bcl-2 bands detected
(Fig. 4B, lane 1). However, the Bcl-2 in FKBP38–Bcl-2 com-
plex showed a considerable decrease in the phosphorylation
by JNK (Fig. 4B, lane 2). To further analyze the eﬀect of
FKBP38 on the Bcl-2 phosphorylation, we next examined
the phosphorylation of Bcl-2D(V35-D64) and Bcl-2D(P65-
V89). Our data demonstrated that Bcl-2D(V35-D64) and
Bcl-2D(P65-V89) showed a diﬀerence in the phosphorylation
reaction; Bcl-2D(V35-D64) showed a marked reduction in
phosphorylation compared to Bcl-2D(P65-V89) (Fig. 4B,
lanes 4 and 6). When FKBP38 interacts with Bcl-2D(V35-
D64), the phosphorylation of Bcl-2D(V35-D64) by JNK
showed a considerable reduction compared to that of Bcl-
2D(P65-V89). Bcl-Xl, a close homolog of Bcl-2, also has been
shown to be phosphorylated in response to external stimuli
[19,20]. To further study the eﬀect of FKBP38 on other
Bcl-2 family protein, we performed JNK-mediated phosphor-
ylation on Bcl-Xl, demonstrating that FKBP38 made little
eﬀect on the phosphorylation of full length human Bcl-Xl
(Fig. 4D, lanes 1 and 2). A mutant form of Bcl-Xl, Bcl-
XlD(M45-A84), showed no phosphorylation by JNK (Fig.
4D, lanes 3 and 4). Taken together, these results suggest that
FKBP38 favorably interacts with Bcl-2 and modulates the
phosphorylation reactions, in unknown and yet to identiﬁed
manner, within the unstructured loop, predominantly the re-
gion containing S70 and S87, by JNK.3.5. Phosphorylation of Bcl-2 inﬂuences molecular interaction
with FKBP38
To address how JNK-mediated phosphorylation in the ﬂex-
ible loop of Bcl-2 aﬀects the interaction between Bcl-2 and
FKBP38, the phosphorylated Bcl-2 was prepared by JNK-
mediated phosphorylation reaction in vitro (Fig. 5A), and
followed by GST pull down assay (Fig. 5B). The phosphory-
lated Bcl-2 was a good substrate for calcineurin after phos-
phorylation by JNK, evident form the band shift from the
higher migrating species to lower migrating species, which
is same as the unphosphorylated form of Bcl-2 (Fig. 5A,
lanes 2 and 3). Our pull down results demonstrated that
the phosphorylated Bcl-2 showed a dramatic decrease in
molecular interaction with FKBP38 (Fig. 5B, lanes 3 and
4), compared to that of the unphosphorylated form of Bcl-
2 (Fig. 5B, lanes 1 and 2). These data suggest that JNK-med-
iated phosphorylation in the highly ﬂexible, disordered loop
of the anti-apoptotic protein Bcl-2 might inﬂuence its interac-
tion with FKBP38.4. Discussion
FKBP38 is a unique protein. It is diﬀerent from typical
FKBP family proteins; it contains a FKBP domain – a domain
which is conserved among FKBP family proteins, a calmodu-
lin-binding domain and three tetratricopeptide repeats, but it
appears to lack conserved residues for FK-506 binding and
Fig. 3. FKBP38 interacts with the unstructured loop of Bcl-2. (A) Loop deletion mutants used in this study are graphically displayed. (B) Co-
expressed complexes of FKBP with a His-tag and Bcl-2 and the Bcl-2 loop deletion mutants with no-tag were puriﬁed by Ni2+–NTA. (C) Loading (L
lanes) and puriﬁed samples from Ni2+–NTA resin (P lanes) were analyzed on 12.5% SDS–PAGE, and subjected to Western blot with anti-Bcl-2 and
FKBP38 antisera. (D) and (E) Yeast two-hybrid experiments were carried out to analyze molecular interaction between FKBP38 and Bcl-2 using
Saccharomyces cerevisiae PJ69-4A with two diﬀerent selection media: SD/()Leu/()Trp (D); SD/()Leu/()Trp/()His (E). For (D) and (E), the
wild type and the deletion mutants of Bcl-2 in the ﬂexible loop were tested: 1, wild type Bcl-2; 2, Bcl-2Dloop:6A; 3, Bcl-2Dloop(H55-V89); 4, Bcl-
2Dloop(P65-V89); 5, Bcl-2Dloop(V35-D64); 6, Bcl-2Dloop(V35-G79).
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15]. Recently, its co-localization with antiapoptotic proteins
Bcl-2 and Bcl-Xl and the inhibition of calcineurin activity in
the absence of FK-506 have been reported [14]. Bcl-2 family
proteins are frequently regulated by posttranslational modiﬁ-
cation that can control their activity and conformation. Bcl-2has been shown to be phosphorylated on some speciﬁc residues
within its unstructured loop under diverse stimuli [7–10]. It was
reported that phosphorylation of Bcl-2 is associated with its
inactivation and mutation of the phosphorylation sites was re-
ported to enhance the antiapoptotic activity of Bcl-2 [16]. The
phosphorylated Bcl-2 was found to be localized at ER and
Fig. 4. FKBP38 aﬀects the phosphorylation of Bcl-2 by JNK. (A) The N-terminal His-tagged wild type Bcl-2 protein (N-His-Bcl-2-wt), the loop
deletion mutant forms of Bcl-2 (N-His-Bcl-2D(p65-V89), N-His-Bcl-2D(V35-D64)), and corresponding Bcl-2-FKBP38 complexes were expressed
E. coli BL21 (DE3) cells, and puriﬁed by the Ni2+–NTA resin, subjected to Western blot using anti-Bcl-2 antisera. (B) The puriﬁed Bcl-2-wt and
mutants were subjected to phosphorylation by JNK with [c-33P]ATP, and analyzed on 15% SDS–PAGE followed by autoradiography for
visualization. (C) His-Bcl-Xl and Bcl-XlD(M45-A84) were puriﬁed, subjected to Western blot using anti-Bcl-Xl antisera, and (D) JNK-mediated
kinase reaction, under the same condition described in (A) and (B), respectively.
1474 C.B. Kang et al. / FEBS Letters 579 (2005) 1469–1476inhibit its binding to proapoptotic proteins [10]. Currently,
biochemical function and speciﬁc molecular regulatory mecha-
nism of FKBP38 with the antiapoptotic proteins are not well
understood.
In this study, we were able to express and purify recombi-
nant FKBP38 from bacteria for biochemical and structural
studies in connection with Bcl-2 family proteins. From ourco-expression, column binding, yeast two-hybrid, and phos-
phorylation studies, we demonstrated that the unstructured
loop region of Bcl-2 was important for the binding between
FKBP38 and Bcl-2. We showed that the stress kinase JNK
was eﬃciently able to phosphorylate the puriﬁed Bcl-2 in vitro
and the phosphorylation of Bcl-2 was extensively inhibited in
the presence of FKBP38. On the other hand, to ask how
Fig. 5. Phosphorylation of Bcl-2 inﬂuences molecular interaction
between FKBP38 and Bcl-2. (A) Puriﬁed Bcl-2 (lane 1) was
phosphorylated by JNK (lane 2) and the phosphorylated Bcl-2 was
puriﬁed by Superdex 75 gel ﬁltration column. The phosphorylation of
Bcl-2 was conﬁrmed by the treatment calcineurin (lane 3). The samples
were analyzed were analyzed on 12.5% SDS–PAGE, and subjected to
Western blot with anti-Bcl-2. (B) The puriﬁed Bcl-2 and P-Bcl-2 were
mixed with 10 lg of GST-FKBP38DTM, and the bindings between
Bcl-2 or P-Bcl-2 and FKBP38 were analyzed by in vitro pull down
assay as described, with 3 lg of Bcl-2 or P-Bcl-2 and 10 lg of GST-
FKBP38DTM: lane 1, Bcl-2 before GST pull down; lane 2, Bcl-2 after
GST pull down; lane 3, P-Bcl-2 before GST pull down; 4, P-Bcl-2 after
GST pull down.
C.B. Kang et al. / FEBS Letters 579 (2005) 1469–1476 1475JNK-mediated phosphorylation on Bcl-2 would aﬀect its inter-
action with FKBP38, we performed GST pull down experi-
ments. Clearly, our data revealed that the phosphorylated
Bcl-2 showed a considerable reduction in its binding with
FKBP38. Taken together, these results suggest that FKBP38
might modulate the phosphorylation in the unstructured loop
of Bcl-2 and could prevent Bcl-2 from being phosphorylated.
On the other hand, a kinase or kinases, including JNK, might
regulate molecular interaction between Bcl-2 and FKBP38
through the phosphorylation.
To address the speciﬁcity of interaction, we carried out
JNK-mediated phosphorylation on Bcl-Xl, which is similar
in function with Bcl-2. Our data showed that Bcl-Xl did not
appear to be aﬀected in the presence of FKBP38; rather our re-
sults showed an indication of a slight increase in the phosphor-
ylation. This suggests that FKBP38 might show a diﬀerence in
molecular interaction with the phosphorylation sites in the
ﬂexible loops of Bcl-2 family proteins. From our deletion mu-
tant analyses, our data suggest that the sites containing or sur-
rounding S70 and S87 in the ﬂexible of Bcl-2 appear to be
important for the physical interaction with FKBP38. Addi-
tional studies need to be done to further characterize the reg-
ulation of FKBP38 on the phosporylation of Bcl-2 with
respect to other sites.In summary, we demonstrated that FKBP38 protein can
interact with Bcl-2, which is consistent with the earlier observa-
tion made by Shirane and Nakayama [14]. The unstructured
loop of Bcl-2 is important for the binding between FKBP38
and Bcl-2 and the binding between Bcl-2 and FKBP38 appears
to aﬀect the phosphorylation of Bcl-2 by JNK. Also, the JNK-
mediated phosphorylation appears to inﬂuence molecular
interaction between Bcl-2 and FKBP38. These new results
might provide an important clue for the additional regulatory
mechanism of Bcl-2 in apoptosis.
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